NeoGenomics, Inc. (NEO) Stock

Healthcare · Diagnostics & Research · Member of Other US Stocks

NeoGenomics, Inc. (NEO) closed at USD 16.88 on 2026-10-14, a change of +70.2 % over the past year, with a market capitalization of USD 2.25B.

NeoGenomics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

NeoGenomics, Inc. key figures

Previous close

USD 16.88 (2026-10-14)

1-year change

+70.2 %

Market cap

USD 2.25B

Enterprise value

USD 2.52B

P/E ratio (trailing)

-43.13

P/E ratio (forward)

50.33

EPS (trailing)

-0.40

EPS (forward)

0.34

PEG ratio

2.09

Price to book

2.81

Revenue growth

11.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.99

Employees

2,500

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About NeoGenomics, Inc.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for NeoGenomics, Inc. and compare it with other stocks.